Johnson & Johnson (NYSE:JNJ) (0.3%) (JNJ — $148.88 — NYSE) is the world’s largest and some of the diversified healthcare corporations, which helps it to climate the COVID-19 disaster higher than most of its friends. The corporate’s pharmaceutical enterprise is without doubt one of the quickest rising within the trade, pushed by a number of important oncology and anti inflammatory merchandise. Johnson & Johnson’s medical system enterprise is recovering shortly from the March halt in non-emergency surgical procedures, and will put up double digit development subsequent yr as they work by the backlog of deferred procedures. Johnson & Johnson has the administration and the robust stability sheet to emerge from this disaster stronger than earlier than.
From Mario Gabelli (Trades, Portfolio)’s Gabelli Asset Fund third-quarter 2020 shareholder commentary.
Concerning the writer:
Sydnee Gatewood
I’m the editorial director at GuruFocus. I’ve a (BA) in journalism and a MA in mass communications from Texas Tech College. I’ve lived in Texas most of my life, but additionally have roots in New Mexico and Colorado. Comply with me on Twitter! @gurusydneerg
